Asle pharmaceuticals

Zaisma

Indications and effects: Erectile dysfunction (patients who are unable to achieve and maintain an erection sufficient for satisfactory sexual activity)

Contraindication

Patients with a history of hypersensitivity to the components of this product.
Patients receiving nitrates or nitric oxide donors (nitroglycerin, amyl nitrite, isosorbide nitrate, nicorandil, etc.)
Patients for whom sexual activity is not recommended, including those with cardiovascular disease (e.g., severe cardiovascular disease such as unstable angina or severe heart failure)
Patients with a history of stroke, myocardial infarction or coronary artery bypass surgery within the past 6 months.
Patients with uncontrolled arrhythmia, hypotension (blood pressure <90/50 mmHg) or uncontrolled hypertension (resting blood pressure >170/100 mmHg)
Genetic degenerative retinal diseases.
Patients with severe hepatic or renal insufficiency.
Patients with congenital QT prolongation (QT prolongation syndrome), patients on Class IA (quinidine, procainamide, disopyramide (oral), cibenzoline, pyrmenol) or Class III antiarrhythmic drugs.
Patients taking other erectile dysfunction medications.
Patients taking HIV protease inhibitors as CYP3A4 inhibitors.

Dosage and Administration

The usual dosage for adults is 100 mg of udenafil orally once a day, approximately one hour before sexual activity.
For patients with organic or mixed erectile dysfunction who do not respond adequately to 100 mg and are judged to tolerate it well, the dose may be increased to 200 mg.
The daily dose should be one time, and the interval between doses should be at least 24 hours.
It can be taken with or without food.

Cautions for use

Pay attention to cardiovascular status before starting treatment for erectile dysfunction, as sexual activity poses a risk to the heart.
Prolonged or sustained erection lasting more than 4 hours (painful erection lasting more than 6 hours) has been reported in a small number of foreign post-marketing adverse events. If symptoms of an erection lasting more than 4 hours are observed, patients should be instructed to seek medical advice immediately because failure to promptly treat persistent erections may result in damage to penile tissue or permanent impairment of erectile function.
Patients should be instructed to discontinue taking the drug and seek immediate medical attention from an ophthalmologist if they experience a sudden decrease in vision or a sudden loss of vision after taking the drug.
Since dizziness and visual disturbance have been observed in clinical trials, caution should be exercised when working at heights, driving a car, or operating other dangerous machinery.
If sudden hearing loss or deafness occurs, discontinue the use of PDE5 inhibitors, including this drug, and instruct the patient to seek immediate medical attention.